OTCMKTS:SPHRY Starpharma (SPHRY) Stock Price, News & Analysis → AI finds its first serious application (From Wall Street Star) (Ad) Free SPHRY Stock Alerts $0.92 +0.07 (+8.24%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.85▼$0.9250-Day Range$0.82▼$0.9652-Week Range$0.77▼$3.30Volume7,148 shsAverage Volume2,877 shsMarket Capitalization$37.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Starpharma alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Starpharma Stock (OTCMKTS:SPHRY)Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.Read More SPHRY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPHRY Stock News HeadlinesMarch 14, 2024 | wsj.comStarpharma Holdings Ltd. ADRFebruary 19, 2024 | markets.businessinsider.comStarpharma's VivaGel Approval Denied By FDAApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.February 18, 2024 | msn.comASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pcJanuary 19, 2024 | morningstar.comStarpharma Holdings Ltd SPLJanuary 6, 2024 | afr.comStarpharma Holdings LimitedNovember 29, 2023 | finance.yahoo.comStarpharma Holdings Limited (SPHRY)November 8, 2023 | investing.comStarpharma Holdings (SPHRY) Earnings Dates & ReportsApril 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.July 27, 2023 | seekingalpha.comStarpharma: Patience Needed, But A Lot To LikeJune 9, 2023 | msn.comThe Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreakOctober 24, 2022 | finance.yahoo.comVIRALEZE Nasal Spray to be distributed in Hong Kong and MacauSeptember 12, 2022 | finance.yahoo.comStarpharma presents compelling data in Prostate Cancer at ESMOAugust 10, 2022 | finance.yahoo.comStarpharma signs new DEP® agreement with MSDJuly 20, 2022 | finanznachrichten.deStarpharma: VIRALEZE Nasal Spray Protects Against Highly Infectious Omicron in Viral Challenge Model - Before or After Viral ExposureJanuary 12, 2022 | nasdaq.comStarpharma Holdings Ltd. ADR (SPHRY)December 13, 2021 | msn.comWhat is happening to the Starpharma (ASX:SPL) share price today?December 6, 2021 | msn.comStarpharma (ASX:SPL) share price shoots 6% higher on Roche agreementNovember 19, 2021 | msn.comWhy is the Starpharma (ASX:SPL) share price trading at 52-week lows?October 28, 2021 | markets.businessinsider.comPerth businesswoman Kim Tran launches new business, scores supply deal with StarpharmaOctober 26, 2021 | msn.comStarpharma (ASX:SPL) share price lifts on supply and distribution dealOctober 8, 2021 | finance.yahoo.comVIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in ItalySeptember 15, 2021 | apnews.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma’s phase 2 clinical-stage cancer treatmentsSeptember 15, 2021 | finance.yahoo.comUS Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatmentsAugust 26, 2021 | msn.comStarpharma (ASX:SPL) share price tanks 3% on 67% revenue dropJuly 26, 2021 | msn.comWhy the Starpharma (ASX:SPL) share price is racing 7% higher todaySee More Headlines Receive SPHRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolOTCMKTS:SPHRY CUSIPN/A CIKN/A Webwww.starpharma.com Phone(138) 532-2700Fax61-3-9510-5955Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$2.83 million Price / Sales13.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.61Miscellaneous Outstanding Shares41,200,000Free FloatN/AMarket Cap$37.90 million OptionableNot Optionable Beta1.19 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Justin CahillCFO & Company SecretaryMs. Cheryl Maley B.Sc. (Age 55)M.B.A., CEO, MD & Director Key CompetitorsData Knights AcquisitionNASDAQ:DKDCAbioAffinity TechnologiesNASDAQ:BIAFHedgePath PharmaceuticalsOTCMKTS:HPPIAIkido PharmaNASDAQ:AIKIInotivNASDAQ:NOTVView All Competitors SPHRY Stock Analysis - Frequently Asked Questions How have SPHRY shares performed in 2024? Starpharma's stock was trading at $1.2440 at the start of the year. Since then, SPHRY shares have decreased by 26.0% and is now trading at $0.92. View the best growth stocks for 2024 here. Are investors shorting Starpharma? Starpharma saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,700 shares, a decline of 70.0% from the March 15th total of 9,000 shares. Based on an average daily trading volume, of 1,400 shares, the short-interest ratio is currently 1.9 days. View Starpharma's Short Interest. How do I buy shares of Starpharma? Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SPHRY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Starpharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.